

HOW DO DOCTORS ASSESS LIFE EXPECTANCY IN CONTEXT OF VOLUNTARY ASSISTED DYING?

EMBARGOED UNTIL 12:01am Monday 25 July 2022

DOCTORS determining a person's eligibility for voluntary assisted dying must assess that person's life expectancy, an "inherently uncertain and imprecise" task made more difficult by the inconsistent wording of each state's legislation, according to the authors of Perspective published today by the *Medical Journal of Australia*.

"In Victoria and South Australia, a person may be eligible for VAD if they have a condition that is 'expected to cause death within weeks or months, not exceeding 6 months' and in Tasmania if the condition is 'expected to cause death within 6 months'," wrote Dr Sharon Nahm and colleagues.

"The legislation in Western Australia and New South Wales states that the condition 'will, on the balance of probabilities, cause death within a period of 6 months.

"In each of these states, a longer period (12 months) is allowed for people with a neurodegenerative disease. In Queensland, the legislation states that the condition is 'expected to cause death within 12 months', without distinguishing the type of condition."

Nahm and colleagues have previously conducted research on the accuracy of oncologists' prognoses about life expectancy of cancer patients which showed that - "most patients in these studies with an expected survival time of less than 6 months died within 6 months".

However, "we have no data about prognostication in people with other terminal illnesses", they said.

"The VAD legislation requires doctors to predict an unspecified probability of a patient dying within a certain period. This is different to the question more commonly asked by patients, which is 'how long have I got?'," Nahm and colleagues wrote in their current article.

"Doctors are not trained to formulate estimates of expected survival time, or to explain them to patients. We predict that many doctors will find it difficult to answer whether they expect individual patients to die within 6 months.

"Our aim is to highlight our uncertainty about which patients are eligible for VAD under current legislation," they wrote.



"Assessing a person's eligibility for VAD is difficult because prognostication is difficult, prognosis is inherently uncertain, and the eligibility criteria are not clearly specified.

"Legislation should be improved by including clearer definitions and explanations of phrases such as 'expected to cause death within 6 months' using probabilistic terminology that corresponds with how prognoses are best formulated and communicated."

All MJA media releases are open access and can be found at: https://www.mja.com.au/journal/media

Please remember to credit The MJA.

The Medical Journal of Australia is a publication of the Australian Medical Association.

The statements or opinions that are expressed in the MJA reflect the views of the authors and do not represent the official policy of the AMA or the MJA unless that is so stated.

CONTACTS: Ivy Shih

Media and Public Relations Adviser | Health & Medicine

University of Sydney

T: +61 2 86279528 | **M:** 0439160475 | **E: Email:**

ivy.shih@sydney.edu.au

Dr Sharon Nahm NHMRC Clinical Trials Centre University of Sydney

Email: sharon.nahm@sydney.edu.au

Dr Belinda Kiely

NHMRC Clinical Trials Centre

University of Sydney

Email: belinda.kiely@sydney.edu.au